The neurofibromatoses. Part 2: NF2 and schwannomatosis

Reviews in Neurological Diseases

Volumn 6, Issue 3, 2009, Pages

  Lu Emerson, Christine ^a   Plotkin, Scott R ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Nerve sheath tumors; Neurofibromatoses; Schwannomatosis; Tumor suppressor, neurogenetic

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ERLOTINIB; MERLIN;

ANALGESIA; BLINDNESS; CAFE AU LAIT SPOT; CANCER CHEMOTHERAPY; CATARACT; CHRONIC PAIN; CLINICAL FEATURE; CRANIAL NERVE; DEPRESSION; DISEASE COURSE; EPENDYMOMA; EPIRETINAL MEMBRANE; EYE EXAMINATION; FACIAL NERVE PARALYSIS; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC LINKAGE; GENOTYPE PHENOTYPE CORRELATION; HAMARTOMA; HEADACHE; HEARING; HEARING LOSS; HUMAN; INTERNAL AUDITORY CANAL; MEDICAL HISTORY; MENINGIOMA; MITOSIS INHIBITION; MOLECULAR BIOLOGY; NERVE FUNCTION; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; NEUROFIBROMATOSIS; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PERIPHERAL NERVE; PERONEUS NERVE PARALYSIS; QUALITY OF LIFE; REVIEW; SCHWANN CELL; SCHWANNOMATOSIS; SEIZURE; SENSITIVITY AND SPECIFICITY; SKIN MANIFESTATION; SPINAL CORD TUMOR; TUMOR ABLATION; VESTIBULAR FUNCTION; VESTIBULOCOCHLEAR NERVE; VISUAL ACUITY; VISUAL DISORDER; WEAKNESS; GENETIC PREDISPOSITION; GENETICS; NEUROMA; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL NERVE;

BLINDNESS; CRANIAL NERVES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MENINGEAL NEOPLASMS; NEURILEMMOMA; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; SPINAL CORD NEOPLASMS; SPINAL NERVES;

EID: 77649248823     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: 10.3909/rind0226B     Document Type: Review

References (34)

1. NIH Consensus Conference. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575-578.
2. MacCollin M, Willett C, Heinrich B, et al. Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology. 2003;60:1968-1974. (Pubitemid 36736014)
3. Lu-Emerson C, Plotkin SR. The neurofibromatoses. Part 1: NF1. Rev Neurol Dis. 2009;6:E47-E53.
4. Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005;26:93-97. (Pubitemid 40130216)
5. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84:603-618.
6. Mulvihill JJ, Parry DM, Sherman JL, et al. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med. 1990;113:39-52.
7. Baser ME, Friedman JM, Wallace AJ, et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology. 2002;59:1759-1765. (Pubitemid 35424459)
8. Nunes F, MacCollin M. Neurofibromatosis 2 in the pediatric population. J Child Neurol. 2003;18:718-724.
9. Ruggieri M, Iannetti P, Polizzi A, et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics. 2005;36:21-34. (Pubitemid 41115326)
10. Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999;81:496-499.
11. Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52:450-461. (Pubitemid 24298996)
12. Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71:715-723.
13. Mautner VF, Tatagiba M, Lindenau M, et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol. 1995;165:951-955.
14. Patronas NJ, Courcoutsakis N, Bromley CM, et al. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology. 2001;218:434-442. (Pubitemid 32121056)
15. Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 2005;19:5-12. (Pubitemid 40824366)
16. Mautner VF, Lindenau M, Baser ME, et al. Skin abnormalities in neurofibromatosis 2. Arch Dermatol. 1997;133:1539-1543.
17. Evans DG, Ramsden RT, Shenton A, et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet. 2007;44:424-428. (Pubitemid 47056867)
18. Kluwe L, Mautner V, Heinrich B, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet. 2003;40:109-114. (Pubitemid 36232815)
19. Wertelecki W, Rouleau GA, Superneau DW, et al. Neurofibromatosis 2: clinical and DNA linkage studies of a large kindred. N Engl J Med. 1988;319:278-283.
20. Rouleau GA, Wertelecki W, Haines JL, et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987;329:246-248. (Pubitemid 17128967)
21. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;75:826.
22. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature. 1993;363:515-521. (Pubitemid 23186636)
23. Curto M, Cole BK, Lallemand D, et al. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol. 2007;177:893-903. (Pubitemid 46873094)
24. Wallace AJ, Watson CJ, Oward E, et al. Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis. Genet Test. 2004;8:368-380.
25. Evans DG, Ramsden RT, Gokhale C, et al. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet. 2007;71:354-358. (Pubitemid 46680801)
26. Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery. 2007;60:460-468. (Pubitemid 46339181)
27. Meijer OW, Vandertop WP, Lagerwaard FJ, Slotman BJ. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2. Neurosurgery. 2008;62(5 suppl):A37-A42.
28. Combs SE, Volk S, Schulz-Ertner D, et al. Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys. 2005;63:75-81. (Pubitemid 41583544)
29. Evans DGR, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43:289-294.
30. Plotkin SR, Singh MA, O'Donnell CC, et al. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008;5:487-491.
31. Antinheimo J, Sankila R, Carpén O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54:71-76. (Pubitemid 30038740)
32. MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology. 2005;64:1838-1845.
33. Hulsebos TJ, Plomp AS, Wolterman RA, et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet. 2007;80:805-810.
34. Jacoby LB, Jones D, Davis K, et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet. 1997;61:1293-1302. (Pubitemid 28046905)